Webinar: HEOR Evidence for Emergent Infectious Diseases

Share on: 
September 16, 2021

Opportunities and challenges in generating and communicating evidence in COVID-19 treatment and vaccine research

Although COVID-19-related disruptions to the pharmaceutical supply chain and to clinical trials created short-term negative impacts for the pharma industry, it also introduced substantial growth opportunities. While companies race to be at the forefront in the development of vaccines and treatments for COVID-19, current strategies for evidence generation and communication of unmet need and product value have to be developed in the context of a rapidly-evolving​ disease landscape. 

As we return to standard reimbursement processes and evidence requirements, we will continue to face challenges from a continually changing environment. 

In this one-hour webinar, we’ll look at the opportunities and challenges that exist when creating HEOR materials in the dynamic COVID-19 setting and outline a set of best practices for developing evidence-based communication materials for emergent infectious diseases. 

What you will learn: 

  • Overview of vaccine and drug development 
  • Key challenges for developing robust literature reviews, dossiers, and economic models 
  • Best practices in COVID-19 research and other emergent diseases 


Shahnaz Khan, MPH 
Executive Director, Market Access and Outcomes Strategy 

Anne Heyes, MBA 
Vice President, Head Market Access and Outcomes Strategy, Europe 

Kati Copley-Merriman, MBA 
Vice President, Market Access and Outcomes Strategy 

Michele Wilson, MSPH 
Senior Director, Health Economics

Related Services:
Conference participants: